MedPath

Alcohol reduction intervention study for TB and/ HIV patients in India

Not Applicable
Conditions
Health Condition 1: Z918- Other specified personal risk factors, not elsewhere classifiedHealth Condition 2: A150- Tuberculosis of lung
Registration Number
CTRI/2020/03/024141
Lead Sponsor
ational Institute on Alcohol Abuse and Alcoholism NIAAA National Institutes of Health NIH
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Active TB,

18+ years Starting TB treatment,

Known HIV status,

AUDIT score more than equal to 8 if male,

AUDIT score more than equal to 4 if female

Exclusion Criteria

already in alcohol treatment

severe medical illness,

cognitive dysfunction or active psychosis,

pregnant

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
- Intervention will result in a greater reduction in drinking days, heavy drinking days and drinks per drinking day, and lower levels of PEth (which is dried blood spot test to confirm alcohol use). <br/ ><br>- Intervention will result in 1) decreased TB treatment default, failure or death (primary), 2) increased TB medication adherence, 3) increased retention in TB care; and among PWH/TB, 4) increased HIV-RNA suppression and 5) increased ART adherence and 6) increased retention in HIV care. <br/ ><br>Timepoint: Measured at 6 and 12 months
Secondary Outcome Measures
NameTimeMethod
To understand multi-level factors that influence alcohol reduction intervention integration into these clinical settings. <br/ ><br>a) evaluate patient, provider and organizational barriers and facilitators to integrated alcohol treatment in TB and HIV/TB settings, and <br/ ><br>b) measure incremental costs from health system and societal perspectives, and to estimate their incremental cost-effectiveness, compared to treatment as usual. <br/ ><br>Timepoint: during the study period for 5 years
© Copyright 2025. All Rights Reserved by MedPath